Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21716911 | 0.99 | GSR (0.36) | GSRESR1ESR2CASP1HSD17B10 | |
| SCHEMBL21716259 | 0.95 | GSR (0.36) | GSRESR1ESR2CASP1HSD17B10 | |
| SCHEMBL22425417 | 0.95 | GSR (0.36) | GSRESR1ESR2CASP1HSD17B10 | |
| SCHEMBL21716262 | 0.95 | GSR (0.37) | GSRESR1ESR2CASP1HSD17B10 | |
| SCHEMBL21716910 | 0.94 | GSR (0.36) | GSRESR1ESR2CASP1HSD17B10 | |
| SCHEMBL21716902 | 0.94 | GSR (0.38) | GSRESR1ESR2CASP1HSD17B10 | |
| SCHEMBL21716971 | 0.92 | GSR (0.35) | GSRESR1ESR2 | |
| SCHEMBL21717153 | 0.91 | GSR (0.33) | GSRESR1ESR2 | |
| SCHEMBL21716260 | 0.88 | TUBB4A (0.38) | GSRESR1ESR2 | |
| SCHEMBL21716942 | 0.88 | GSR (0.35) | GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192884-B2 | Heterocyclic compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2021-12-07 | — | — | US | disclosed |
| US-20200048226-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192884-B2 | Heterocyclic compound and organic light-emitting device comprising same | CYP1A1, CYP1B1, CRY1 | GSR 3951/4885ESR1 195/4885ESR2 1326/4885 |
| US-20200048226-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CYP1A1, CYP1B1, CRY1 | GSR 3951/4885ESR1 195/4885ESR2 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.